GALT Galectin Forward P/S Multiple

Galectin Therapeutics Inc. (GALT) - corporate logo

The development of liver fibrosis treatments remains limited to the laboratory stage and is dependent on significant capital. This forward P/S chart for Galectin Therapeutics (GALT) on the GURU.Markets platform reveals the current trend, where shows the actual value of the metric. The absence of proprietary manufacturing plants minimizes costs for Galectin Therapeutics, yet geopolitical tensions and sanctions are seriously hindering international clinical trials of the drugs.

GALT Galectin Therapeutics Inc.: Price-to-Projected Revenue Ratio in the range 07/04/2022 - 11/13/2026

Summary analytical data breakdowns for galectintherapeutics.com (GALT)

- current price and projected stock value:
Stock Price Galectin Therapeutics Inc.|GALT - Analyst Target Range
- market capitalization data:
Market Capitalization Galectin Therapeutics Inc.|GALT - Enterprise Value
- issuer book value statistics:
Net Assets per Single Share Galectin Therapeutics|GALT - Company Book Value|Market Capitalization to Book Value Ratio galectintherapeutics.com|GALT - Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Galectin Therapeutics|GALT - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Galectin Therapeutics Inc.|GALT - Company Cumulative Indebtedness|Debts to Book Capitalization Galectin Therapeutics Inc.|GALT - Long-Term Debt Volume|Company Short-Term Debt Galectin Therapeutics|Quick Liquidity Indicator galectintherapeutics.com
- business earnings and investment ratios data:
GALT - Final Profit|Future Profit Galectin Therapeutics|GALT - Market Price to Net Income Ratio|Forward P/E Multiple Galectin Therapeutics Inc.|GALT - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Galectin Therapeutics Inc.|GALT - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Galectin Therapeutics|GALT - Earnings per share for the trailing year|Quarterly EPS earnings growth galectintherapeutics.com|GALT - Earnings growth in current year|Net earnings per share growth forecast for next year Galectin Therapeutics
- sales revenue and business income indicators:
GALT - Company Annual Revenue|Projected Sales Volume Galectin Therapeutics Inc.|GALT - Price to Sales|Forward Price-to-Revenue Multiple Galectin Therapeutics Inc.
General company analysis:Galectin GALT
Product sample of Galectin Therapeutics, Inc.

The forward P/S ratio compares the current market capitalization of Galectin Therapeutics (GALT) with expected revenue, allowing for a determination of the premium paid for future cash flows. By analyzing the forward P/S metric, an investor assesses the fairness of the market value of Galectin Therapeutics (GALT), whose developments in liver fibrosis therapy and the fight against cirrhosis determine the long-term growth potential of its fundamental value.

Analysis of competing companies

Forward P/S Multiple ARWR (Arrowhead Pharmaceuticals, Inc.)|Projected Price to Revenue Mirum Pharmaceuticals, Inc.|Dynavax Pharma - Forward P/S Multiple|ABUS - Forward P/S Multiple|Inventiva S.A. (IVA) - Price-to-Projected Revenue Ratio|GYRE (gyretx.com) - Price-to-Projected Revenue Ratio|ASMB (Assembly Biosciences, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Genfit Corp GNFT|Forward P/S Multiple DRRX|Forward Price-to-Revenue Multiple aligos.com ALGS|BioVie - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio GLMD (Galmed Pharmaceuticals Ltd)|ENDRA Life Sciences Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Hepion Pharmaceuticals HEPA